• Mark W Tenforde, Samantha M Olson, Wesley H Self, H Keipp Talbot, Christopher J Lindsell, Jay S Steingrub, Nathan I Shapiro, Adit A Ginde, David J Douin, Matthew E Prekker, Samuel M Brown, Ithan D Peltan, Michelle N Gong, Amira Mohamed, Akram Khan, Matthew C Exline, D Clark Files, Kevin W Gibbs, William B Stubblefield, Jonathan D Casey, Todd W Rice, Carlos G Grijalva, David N Hager, Arber Shehu, Nida Qadir, Steven Y Chang, Jennifer G Wilson, Manjusha Gaglani, Kempapura Murthy, Nicole Calhoun, Arnold S Monto, Emily T Martin, Anurag Malani, Richard K Zimmerman, Fernanda P Silveira, Donald B Middleton, Yuwei Zhu, Dayna Wyatt, Meagan Stephenson, Adrienne Baughman, Kelsey N Womack, Kimberly W Hart, Miwako Kobayashi, Jennifer R Verani, Manish M Patel, IVY Network, and HAIVEN Investigators.
• MMWR Morb. Mortal. Wkly. Rep. 2021 May 7; 70 (18): 674-679.

AbstractAdults aged ≥65 years are at increased risk for severe outcomes from COVID-19 and were identified as a priority group to receive the first COVID-19 vaccines approved for use under an Emergency Use Authorization (EUA) in the United States (1-3). In an evaluation at 24 hospitals in 14 states,* the effectiveness of partial or full vaccination† with Pfizer-BioNTech or Moderna vaccines against COVID-19-associated hospitalization was assessed among adults aged ≥65 years. Among 417 hospitalized adults aged ≥65 years (including 187 case-patients and 230 controls), the median age was 73 years, 48% were female, 73% were non-Hispanic White, 17% were non-Hispanic Black, 6% were Hispanic, and 4% lived in a long-term care facility. Adjusted vaccine effectiveness (VE) against COVID-19-associated hospitalization among adults aged ≥65 years was estimated to be 94% (95% confidence interval [CI] = 49%-99%) for full vaccination and 64% (95% CI = 28%-82%) for partial vaccination. These findings are consistent with efficacy determined from clinical trials in the subgroup of adults aged ≥65 years (4,5). This multisite U.S. evaluation under real-world conditions suggests that vaccination provided protection against COVID-19-associated hospitalization among adults aged ≥65 years. Vaccination is a critical tool for reducing severe COVID-19 in groups at high risk.

19 keywords...

hide…